Compare BridgeBio Pharma Inc (BBIO) vs Vanguard Sht-Term Inflation-Protected Sec Idx ETF (VTIP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Vanguard Sht-Term Inflation-Protected Sec Idx ETF — how do they compare? BridgeBio Pharma Inc trades at $82.82 (market cap $16.46B), while Vanguard Sht-Term Inflation-Protected Sec Idx ETF trades at $49.66. The key difference: BridgeBio Pharma Inc is trading nearer its 52-week high, Vanguard Sht-Term Inflation-Protected Sec Idx ETF nearer its low. Which is the better fit depends on your goals.
| BBIO | VTIP | |
|---|---|---|
Market Cap | $16.46B | — |
Sector | Health | — |
52-Week High | $90.17 | $50.75 |
52-Week Low | $44.81 | $49.39 |
Enterprise Value | $18.02B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $83.08, down 3.27% today, near its 52-week high. The stock shows bullish technical momentum with strong moving averages, while fundamentals reveal rapid revenue growth to $502M in 2025 but persistent losses with a -144.4% net margin. Recent news highlights regulatory approvals for acoramidis and a $1B preferred equity raise to fund launches, driving positive sentiment despite earnings misses.
Outlook remains speculative with high execution risk; analyst consensus is strongly bullish (92% buy) targeting $104.57, but profitability challenges and heavy cash burn require successful pipeline commercialization to justify valuation. Key near-term catalysts include FDA decisions on BBP-418 and encaleret in 2026.
VTIP trades at $49.61, down slightly by 0.06% with a bearish technical signal from moving averages. The ETF focuses on short-term inflation-protected securities, offering investors protection against persistent inflation currently running at 3.8%. Recent institutional activity shows mixed positioning with several firms increasing holdings while others trimmed positions. The overall technical picture remains cautious despite neutral oscillator readings.
VTIP provides inflation hedging with potential 3.8% returns in the current environment, though the Fed's reluctance to cut rates in 2026 presents headwinds. The ETF's short-term TIPS focus reduces duration risk but remains sensitive to inflation expectations and monetary policy shifts. Key risks include interest rate volatility and inflation trajectory uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Vanguard Sht-Term Inflation-Protected Sec Idx ETF
The index is a market-capitalization-weighted index that includes all inflation-protected public obligations issued by the US Treasury with remaining maturities of less than 5 years. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the securities that make up the index, holding each security in approximately the same proportion as its weighting in the index.
Read more on VTIP →
